$GRAL Stock Drop: GRAIL, Inc. Investors Notified of the Securities Fraud Class Action to Recover Losses Over Trial Results
Bleichmar Fonti & Auld LLP announced a class action lawsuit has been filed against GRAIL, Inc. on behalf of investors alleging securities fraud related to the NHS-Galleri cancer trial. The lawsuit follows a 50.55% stock drop in February 2026 after GRAIL disclosed the trial did not meet its primary endpoint of reducing late-stage cancers. Investors have until August 4, 2026 to seek appointment as lead plaintiff in the case pending in the U.S.
Key figures
- Post drop price
- $50.21
- Prior close price
- $101.53
- Stock drop percent
- 50.55%
- Share decline amount
- $51.32
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.